These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 26572762)

  • 1. Tau imaging in neurodegenerative diseases.
    Dani M; Brooks DJ; Edison P
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1139-50. PubMed ID: 26572762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging biomarkers in tauopathies.
    Dani M; Edison P; Brooks DJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S26-8. PubMed ID: 26299160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.
    Lemoine L; Gillberg PG; Svedberg M; Stepanov V; Jia Z; Huang J; Nag S; Tian H; Ghetti B; Okamura N; Higuchi M; Halldin C; Nordberg A
    Alzheimers Res Ther; 2017 Dec; 9(1):96. PubMed ID: 29229003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
    Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
    Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.
    Wang YT; Edison P
    Curr Neurol Neurosci Rep; 2019 Jun; 19(7):45. PubMed ID: 31172290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in Tau PET Imaging.
    Zimmer ER; Leuzy A; Gauthier S; Rosa-Neto P
    Can J Neurol Sci; 2014 Sep; 41(5):547-53. PubMed ID: 25424608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau PET imaging in neurodegenerative tauopathies-still a challenge.
    Leuzy A; Chiotis K; Lemoine L; Gillberg PG; Almkvist O; Rodriguez-Vieitez E; Nordberg A
    Mol Psychiatry; 2019 Aug; 24(8):1112-1134. PubMed ID: 30635637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau imaging: early progress and future directions.
    Villemagne VL; Fodero-Tavoletti MT; Masters CL; Rowe CC
    Lancet Neurol; 2015 Jan; 14(1):114-24. PubMed ID: 25496902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo tau imaging: obstacles and progress.
    Villemagne VL; Okamura N
    Alzheimers Dement; 2014 Jun; 10(3 Suppl):S254-64. PubMed ID: 24924676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions.
    Villemagne VL; Okamura N
    Curr Opin Neurobiol; 2016 Feb; 36():43-51. PubMed ID: 26397020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers.
    Shah M; Catafau AM
    J Nucl Med; 2014 Jun; 55(6):871-4. PubMed ID: 24833492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head to head comparison of [
    Jang YK; Lyoo CH; Park S; Oh SJ; Cho H; Oh M; Ryu YH; Choi JY; Rabinovici GD; Kim HJ; Moon SH; Jang H; Lee JS; Jagust WJ; Na DL; Kim JS; Seo SW
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):432-442. PubMed ID: 29143870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue.
    Aguero C; Dhaynaut M; Normandin MD; Amaral AC; Guehl NJ; Neelamegam R; Marquie M; Johnson KA; El Fakhri G; Frosch MP; Gomez-Isla T
    Acta Neuropathol Commun; 2019 Mar; 7(1):37. PubMed ID: 30857558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.
    Villemagne VL; Doré V; Burnham SC; Masters CL; Rowe CC
    Nat Rev Neurol; 2018 Apr; 14(4):225-236. PubMed ID: 29449700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of Tau Pathology in Neurodegenerative Diseases: An Update.
    Beyer L; Brendel M
    Semin Nucl Med; 2021 May; 51(3):253-263. PubMed ID: 33353724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau PET imaging in Alzheimer's disease.
    Okamura N; Harada R; Furumoto S; Arai H; Yanai K; Kudo Y
    Curr Neurol Neurosci Rep; 2014 Nov; 14(11):500. PubMed ID: 25239654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau PET imaging: present and future directions.
    Saint-Aubert L; Lemoine L; Chiotis K; Leuzy A; Rodriguez-Vieitez E; Nordberg A
    Mol Neurodegener; 2017 Feb; 12(1):19. PubMed ID: 28219440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies.
    Choi Y; Ha S; Lee YS; Kim YK; Lee DS; Kim DJ
    Nucl Med Mol Imaging; 2018 Feb; 52(1):24-30. PubMed ID: 29391909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau imaging with PET: an overview of challenges, current progress, and future applications.
    Robertson JS; Rowe CC; Villemagne VL
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):405-413. PubMed ID: 28750496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of [
    Tezuka T; Takahata K; Seki M; Tabuchi H; Momota Y; Shiraiwa M; Suzuki N; Morimoto A; Nakahara T; Iwabuchi Y; Miura E; Yamamoto Y; Sano Y; Funaki K; Yamagata B; Ueda R; Yoshizaki T; Mashima K; Shibata M; Oyama M; Okada K; Kubota M; Okita H; Takao M; Jinzaki M; Nakahara J; Mimura M; Ito D
    Brain Commun; 2021; 3(4):fcab190. PubMed ID: 34632382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.